Literature DB >> 21896243

Plasma appearance and disappearance of an oral dose of 25-hydroxyvitamin D2 in healthy adults.

Kerry S Jones1, Inez Schoenmakers, Les J C Bluck, Shujing Ding, Ann Prentice.   

Abstract

25-Hydroxyvitamin D (25(OH)D) half-life is a potential biomarker for investigating vitamin D metabolism and requirements. We performed a pilot study to assess the approach and practical feasibility of measuring 25(OH)D half-life after an oral dose. A total of twelve healthy Gambian men aged 18-23 years were divided into two groups to investigate the rate and timing of (1) absorption and (2) plasma disappearance after an 80 nmol oral dose of 25(OH)D2. Fasting blood samples were collected at baseline and, in the first group, every 2 h post-dose for 12 h, at 24 h, 48 h and on day 15. In the second group, fasting blood samples were collected on days 3, 4, 5, 6, 9, 12, 15, 18 and 21. Urine was collected for 2 h after the first morning void at baseline and on day 15. 25(OH)D2 plasma concentration was measured by ultra-performance liquid chromatography-tandem MS/MS and corrected for baseline. Biomarkers of vitamin D, Ca and P metabolism were measured at baseline and on day 15. The peak plasma concentration of 25(OH)D2 was 9·6 (sd 0·9) nmol/l at 4·4 (sd 1·8) h. The terminal slope of 25(OH)D2 disappearance was identified to commence from day 6. The terminal half-life of plasma 25(OH)D2 was 13·4 (sd 2·7) d. There were no significant differences in plasma 25(OH)D3, total 1,25(OH)2D, parathyroid hormone, P, Ca and ionised Ca and urinary Ca and P between baseline and day 15 and between the two groups. The present study provides data on the plasma response to oral 25(OH)D2 that will underpin and contribute to the further development of studies to investigate 25(OH)D half-life.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21896243      PMCID: PMC3328847          DOI: 10.1017/S0007114511004132

Source DB:  PubMed          Journal:  Br J Nutr        ISSN: 0007-1145            Impact factor:   3.718


  59 in total

1.  Intestinal absorption of cholecalciferol and 25-hydroxycholecalciferol in chronic cholestatic liver disease.

Authors:  M D Sitrin; J M Bengoa
Journal:  Am J Clin Nutr       Date:  1987-12       Impact factor: 7.045

2.  Serum 25-hydroxyvitamin D in a West African population of tuberculosis patients and unmatched healthy controls.

Authors:  Christian Wejse; Rikke Olesen; Paulo Rabna; Pernille Kaestel; Per Gustafson; Peter Aaby; Paul L Andersen; Henning Glerup; Morten Sodemann
Journal:  Am J Clin Nutr       Date:  2007-11       Impact factor: 7.045

3.  Treatment and prevention of vitamin D insufficiency in cystic fibrosis patients: comparative efficacy of ergocalciferol, cholecalciferol, and UV light.

Authors:  Natasha B Khazai; Suzanne E Judd; Leo Jeng; Linda L Wolfenden; Arlene Stecenko; Thomas R Ziegler; Vin Tangpricha
Journal:  J Clin Endocrinol Metab       Date:  2009-03-31       Impact factor: 5.958

4.  Absorption of vitamin D3-3H in control subjects and patients with intestinal malabsorption.

Authors:  G R Thompson; B Lewis; C C Booth
Journal:  J Clin Invest       Date:  1966-01       Impact factor: 14.808

5.  Acute administration of 25-hydroxycholecalciferol in man.

Authors:  J G Haddad; S Rojanasathit
Journal:  J Clin Endocrinol Metab       Date:  1976-02       Impact factor: 5.958

6.  A new mechanism for induced vitamin D deficiency in calcium deprivation.

Authors:  M R Clements; L Johnson; D R Fraser
Journal:  Nature       Date:  1987 Jan 1-7       Impact factor: 49.962

Review 7.  Vitamin D3 distribution and status in the body.

Authors:  Robert P Heaney; Ronald L Horst; Diane M Cullen; Laura A G Armas
Journal:  J Am Coll Nutr       Date:  2009-06       Impact factor: 3.169

8.  Comparison of vitamin D and 25-hydroxyvitamin D absorption in the rat.

Authors:  M D Sitrin; K L Pollack; M J Bolt; I H Rosenberg
Journal:  Am J Physiol       Date:  1982-04

9.  Changes in plasma half-life and clearance of 3H-25-hydroxyvitamin D3 in patients with intestinal malabsorption.

Authors:  A J Batchelor; G Watson; J E Compston
Journal:  Gut       Date:  1982-12       Impact factor: 23.059

10.  Plasma levels and intestinal absorption of 25-hydroxyvitamin D in patients with small bowel resection.

Authors:  J E Compston; B Creamer
Journal:  Gut       Date:  1977-03       Impact factor: 23.059

View more
  15 in total

Review 1.  The clinical use of vitamin D metabolites and their potential developments: a position statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF).

Authors:  Luisella Cianferotti; Claudio Cricelli; John A Kanis; Ranuccio Nuti; Jean-Y Reginster; Johann D Ringe; Rene Rizzoli; Maria Luisa Brandi
Journal:  Endocrine       Date:  2015-05-01       Impact factor: 3.633

2.  Vitamin D kinetics in nonpregnant and pregnant women after a single oral dose of trideuterated vitamin D3.

Authors:  Cora M Best; Robert Sherwood; Janet A Novotny; Sheng Zhang; Eva K Pressman; Kimberly O O'Brien
Journal:  J Steroid Biochem Mol Biol       Date:  2021-11-26       Impact factor: 4.292

3.  Vitamin D3 supplementation scheme in HIV-infected patients based upon pharmacokinetic modelling of 25-hydroxycholecalciferol.

Authors:  Frantz Foissac; Jean-Marc Tréluyer; Jean-Claude Souberbielle; Hafeda Rostane; Saïk Urien; Jean-Paul Viard
Journal:  Br J Clin Pharmacol       Date:  2013-05       Impact factor: 4.335

4.  The problems of vitamin d insufficiency in older people.

Authors:  Barbara J Boucher
Journal:  Aging Dis       Date:  2012-06-06       Impact factor: 6.745

5.  Predictors of 25(OH)D half-life and plasma 25(OH)D concentration in The Gambia and the UK.

Authors:  K S Jones; S Assar; D Vanderschueren; R Bouillon; A Prentice; I Schoenmakers
Journal:  Osteoporos Int       Date:  2014-10-03       Impact factor: 4.507

6.  Predictors of intact and C-terminal fibroblast growth factor 23 in Gambian children.

Authors:  Vickie Braithwaite; Kerry S Jones; Shima Assar; Inez Schoenmakers; Ann Prentice
Journal:  Endocr Connect       Date:  2013-12-19       Impact factor: 3.335

7.  Vitamin D binding protein genotype is associated with plasma 25OHD concentration in West African children.

Authors:  V S Braithwaite; K S Jones; I Schoenmakers; M Silver; A Prentice; B J Hennig
Journal:  Bone       Date:  2015-01-31       Impact factor: 4.398

8.  Differences in 25-Hydroxyvitamin D Clearance by eGFR and Race: A Pharmacokinetic Study.

Authors:  Simon Hsu; Leila R Zelnick; Yvonne S Lin; Cora M Best; Bryan Kestenbaum; Kenneth E Thummel; Lynn M Rose; Andrew N Hoofnagle; Ian H de Boer
Journal:  J Am Soc Nephrol       Date:  2020-10-28       Impact factor: 14.978

9.  25(OH)D2 half-life is shorter than 25(OH)D3 half-life and is influenced by DBP concentration and genotype.

Authors:  K S Jones; S Assar; D Harnpanich; R Bouillon; D Lambrechts; A Prentice; I Schoenmakers
Journal:  J Clin Endocrinol Metab       Date:  2014-06-02       Impact factor: 5.958

10.  Vitamin D expenditure is not altered in pregnancy and lactation despite changes in vitamin D metabolite concentrations.

Authors:  Kerry S Jones; Shima Assar; Ann Prentice; Inez Schoenmakers
Journal:  Sci Rep       Date:  2016-05-25       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.